Roche Gets FDA Approval for First Companion Diagnostic to Detect Gene Mutation Linked with a Type of Lung Cancer - Clinical Lab Products

首页> 外文期刊>Clinical Lab Products >Roche Gets FDA Approval for First Companion Diagnostic to Detect Gene Mutation Linked with a Type of Lung Cancer - Clinical Lab Products

【24h】

Roche Gets FDA Approval for First Companion Diagnostic to Detect Gene Mutation Linked with a Type of Lung Cancer - Clinical Lab Products

机译：罗氏公司获得用于首次伴侣诊断的FDA批准以检测与一种肺癌相关的基因突变-临床实验室产品

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Lab Products》 |2013年第2013期|共页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类实验医学、医学实验;
关键词

相似文献

外文文献
中文文献
专利

1. Roche Gets FDA Approval for First Companion Diagnostic to Detect Gene Mutation Linked with a Type of Lung Cancer - Clinical Lab Products [J] . Clinical Lab Products . 2013,第2013期

机译：罗氏公司获得用于首次伴侣诊断的FDA批准以检测与一种肺癌相关的基因突变-临床实验室产品
2. Dako Receives FDA Approval for Companion Diagnostics - Clinical Lab Products [J] . Clinical Lab Products . 2012,第2012期

机译：Dako获得伴随诊断的FDA批准-临床实验室产品
3. Dako Receives FDA Approval for Companion Diagnostics - Clinical Lab Products [J] . Clinical Lab Products . 2012,第2012期

机译：Dako获得伴随诊断的FDA批准-临床实验室产品
4. Comparison of Expression, Copy Number, miRNA, and Mutation Data for Clinical Biomarker Identification in Breast and Lung Cancer Using Three Algorithms [C] . Hugo Gomez-Rueda, Rebeca Palacios-Corona, Victor Trevino-Alvarado International Molecular Medicine Tri-Conference. . 2015

机译：使用三种算法比较乳腺癌生物标志物临床生物标志物鉴定的表达，拷贝数，miRNA和突变数据
5. A Prognostic and Predictive Computational Pathology Based Companion Diagnostic Approach: Precision Medicine for Lung Cancer [D] . ?Wang, Xiangxue 2019

机译：基于预测和预测计算病理的伴随诊断方法：肺癌精密药物
6. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1- RET- AXL- PDGFR-α- NTRK1-) Non-Small Cell Lung Cancer Globally? [O] . Sai-Hong Ignatius Ou, Ross A. Soo, Akihito Kubo, 2014

机译：美国FDA同时开发同伴诊断（CDx）的要求是否会延迟对RTK重排的（ROS1-RET-AXL-PDGFR-α-NTRK1-）非小型受体酪氨酸激酶抑制剂的批准全球细胞肺癌？
7. Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase (RTK) inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-a-, NTRK1-) non-small cell lung cancer globally? [O] . Sai-Hong Ignatius Ou 2014

机译：美国FDa同时共同开发伴随诊断（CDx）的要求是否会延迟批准RTK重排的受体酪氨酸激酶（RTK）抑制剂（ROs1-，RET-，aXL-，pDGFR-a-，NTRK1-）全球非小细胞肺癌？

Roche Gets FDA Approval for First Companion Diagnostic to Detect Gene Mutation Linked with a Type of Lung Cancer - Clinical Lab Products

著录项

相似文献

相关主题

期刊订阅